Researchers from Würzburg and Stony Brook have found a new weak spot in the bacterium that causes tuberculosis: Blocking a specific enzyme involved in the cholesterol catabolism could disable the bacteria.
In 2012, there were around 8.6 million cases of tuberculosis worldwide resulting in 1.3 million associated deaths according to the World Health Organisation WHO. About five percent of infections were caused by multidrug-resistant pathogens, a trend that is on the rise.
Scientists are therefore seeking new effective ways to tackle the tuberculosis bacteria in the future. Professor Caroline Kisker and her team have devoted their research to this topic: At the University of Würzburg’s Rudolf-Virchow-Center for Experimental Biomedicine, they are studying the bacterial enzymes to pinpoint new vulnerable points.
Enzyme-steroid interaction opens up new prospects
The Würzburg researchers are looking into the pathogens' cholesterol metabolism among others. The enzyme FadA5 is of major interest in this context as it is needed by the bacillus to keep up chronic infection. Teaming up with researchers of Stony Brook University (US), Kisker and her team have now analysed the exact structure of the enzyme – and identified a potential new target for drugs.
"We inserted a steroid molecule into the enzyme's active centre and analysed the resulting structure," the Würzburg professor explains. This finding helps to design molecules that fit exactly into the active centre and block it with the aim to completely disable the enzyme FadA5, as the research group reports in the January issue of "Structure" journal.
Drug specifically targets the bacterium
A potential problem, however, is that the human organism uses enzymes which are similar to the FadA5 from the tuberculosis bacilli. Hence, it is conceivable that a new drug not only affects the bacteria, but harms the human body as well.
Therefore, Kisker's team analysed the human enzymes, too. The result was promising: "Comparing the structures showed that it should be possible to block the bacterial enzyme specifically," the professor further. Thus, an inhibiting drug should only harm the bacteria but not the human enzymes.
"The steroid is a solid basis for us to develop new inhibiting drugs," Kisker says. To pursue this goal, she has teamed up with other work groups, including that of Professor Christoph Sotriffer of the Würzburg Pharmaceutical Chemistry Department. Their aim is to find a drug that specifically inhibits the FadA5 enzyme of the tuberculosis pathogens.
Schaefer et al.: "FadA5 a thiolase from Mycobacterium tuberculosis – a unique steroid-binding pocket reveals the potential for drug development against tuberculosis", Structure, published online, 2014, December 4, DOI: http://dx.doi.org/10.1016/j.str.2014.10.010
Prof. Dr. Caroline Kisker, Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Phone +49 931 31-80381, email@example.com
Robert Emmerich | Julius-Maximilians-Universität Würzburg
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences